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Abstract
Purpose—Postpartum depression (PPD) occurs in 10%–15% of women. The appetite hormone 
ghrelin, which fluctuates during pregnancy, is associated with depression in nonpregnant samples. 
Here, we examine the association between PPD and active ghrelin from pregnancy to postpartum. 
We additionally examine whether ghrelin changes from pregnancy to postpartum and differs 
between breastfeeding and non-breastfeeding women.
Methods—Sixty women participated in a survey examining PPD and had information in regard 
to ghrelin concentrations were included in the study. The Edinburgh Postnatal Depression Scale 
was used to assess symptoms of PPD. Raw ghrelin levels and ghrelin levels adjusted for creatinine 
were included as outcomes.
Results—Women screening positive for PPD at 12-weeks postpartum had higher pregnancy 
ghrelin concentrations. Ghrelin concentrations significantly decreased from pregnancy to 6-weeks 
postpartum and this change differed based on pregnancy depression status. Finally, ghrelin levels 
were lower in women who breastfed compared with women who were bottle-feeding. No 
significant findings remained once ghrelin levels were adjusted for creatinine.
Conclusions—Although results do not suggest an association between PPD and ghrelin after 
adjusting for creatinine, future research should continue to explore this possibility extending 
further across the postpartum period with larger sample sizes.
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Major depression is a common psychiatric disorder with a lifetime prevalence of 
approximately 17% (Kessler et al. 2005; Kessler et al. 1994). Although the etiology of major 
depression is unclear, biological factors are likely involved. For example, vulnerability to 
depression increases in females during periods of substantial reproductive hormone change, 
including puberty (Nolen-Hoeksema and Girgus 1994), perimenopause (Schmidt et al. 
2004), and postpartum. After childbirth, approximately 15% of women suffer postpartum 
depression (PPD; defined as a major depressive episode with onset within the 4-weeks post-
delivery) (Gaynes et al. 2005; Pearlstein et al. 2009) and 40% to 80% develop transient, 
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milder symptoms (Flores and Hendrick 2002). Women who have experienced a previous 
major depressive episode are at the greatest risk for developing PPD (Cohen et al. 2006). 
PPD, in part, is thought to be due to the rapid and substantial gonadal steroid changes that 
occur during postpartum (Bloch et al. 2003). However, no consistent associations between 
estradiol and progesterone concentrations and PPD have been identified. Given the 
significant impact PPD can have on the new mother and her newborn, elucidating the factors 
involved in vulnerability is essential (Field 2010).
The hormone ghrelin, best known for its roles in meal initiation and nutrient sensing 
(Cummings et al. 2001; Sun et al. 2008; Wang et al. 2008), also modulates reproduction by 
regulating hormone secretion from the brain and affecting gonadal tissue development and 
steroidogenesis (Angelidis et al. 2012). Ghrelin fluctuates over the course of pregnancy and 
postpartum, peaking in the second trimester, declining steadily thereafter, and reaching its 
lowest concentration at the end of the third trimester (Fuglsang et al. 2005; Palik et al. 
2007). Ghrelin concentrations are lower in pregnant compared with nonpregnant healthy 
women (Larson-Meyer et al. 2010) and, among postpartum women, vary as a function of 
lactation. Specifically, significantly lower ghrelin concentrations are observed in non-
lactating/bottle-feeding women compared with women who breastfeed for ≥ 6 months 
(Stuebe et al. 2011) but not compared to those who breastfeed for ~1 month (Larson-Meyer 
et al. 2010).
There is also mounting evidence that ghrelin plays a regulatory role in mood and sleep 
(Chuang and Zigman 2010; Lutter et al. 2008; Steiger et al. 2011), both of which often show 
significant change during pregnancy and postpartum. Exogenous administration of ghrelin is 
associated with significantly less depression-like symptoms in animal models of depression 
(Lutter et al. 2008; Steiger et al. 2011). In humans, patients with depression exhibit a 
significantly lower ghrelin concentration (Barim et al. 2009) and different frequencies of the 
Leu72Met ghrelin gene variants (Nakashima et al. 2008) than controls. Moreover, there is 
suggestive evidence that ghrelin administration in humans improves mood in some healthy 
(Schmid et al. 2005) and depressed (Kluge et al. 2011) individuals.
In addition, ghrelin seems to exert sleep-promoting effects. Ghrelin knockout mice sleep less 
than wild type mice (Szentirmai et al. 2007); and, in humans, nocturnal ghrelin 
concentration is blunted during sleep deprivation (Dzaja et al. 2004) but elevated during the 
day and evening following sleep deprivation (Schmid et al. 2008; Spiegel et al. 2004). Given 
that ghrelin fluctuates across pregnancy and postpartum and is associated with the changes 
in mood and sleep often observed during this time, it stands to reason that PPD status may 
influence ghrelin concentrations.
The purpose of this exploratory study is two-fold. First, we examine preliminary 
associations between ghrelin concentrations and depressive symptoms from pregnancy to 
postpartum. Second, we explore ghrelin concentration changes across pregnancy and 
postpartum and the influence of breastfeeding on ghrelin levels. We do not make a priori 
hypotheses about results or the directionality of the findings as this study is preliminary in 
nature and initial findings will be important in generating hypotheses about changes in 
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ghrelin concentration over the course of pregnancy and postpartum and the potential 
association between ghrelin and PPD.
MATERIALS AND METHODS
Participants
The current sample includes a subsample of 60 women who are part of a larger survey 
examining PPD in patients from a public health prenatal clinic. Because these secondary 
analyses were not a planned analysis of the parent study, the selection of this subsample of 
women was based on the availability of a urine sample. For the overarching survey, eligible 
patients had to be 18–42 years-old. Medical records were reviewed to identify potential 
participants attending the public health prenatal clinic, who were then described the study by 
clinic nurses. Potential participants then provided written informed consent and were 
screened for participation at 31–33 weeks of pregnancy. Because a previous major 
depressive episode significantly increases risk for the development of PPD, approximately 
half of the overarching study sample was selected based on a positive screen for previous 
depressed mood or anhedonia for at least 2 weeks. For eligible participants, baseline 
measures were completed during pregnancy at 35–36 weeks and follow-up measurements 
were repeated at 6- and 12-weeks postpartum.
The following exclusion criteria were included within the larger survey: 1) history of a 
psychotic/bipolar disorder or substance dependence (or recent use of street drugs or alcohol 
during pregnancy); 2) eating disorder diagnosis in the past 2 years; 3) body mass index 
(BMI) > 35 or < 18.5; 4) chronic or acute serious medical illness or pregnancy 
complications; 5) medications during the two weeks prior to the home visit at 35–36 weeks 
of pregnancy or during the protocol (except vitamins, iron, acetaminophen, 
diphenhydramine or for pain control during labor and delivery and short duration treatments 
for brief, mild illnesses); 6) cigarette smoking; and 7) not fluent in spoken and written 
English or Spanish.
All assessments were completed during home visits. Questionnaires were administered, and 
interviews were conducted, in English or Spanish depending on the primary language of the 
participant. The current subsample consisted of young women (M=26.90; SD=6.0 years) 
who were over-representative of racial/ethnic minorities in the local community: 17% of 
women self-identified as Caucasian, 3% Asian, 2% Native American, and 78% “Other;” 
87% of the sample self-reported Hispanic ethnicity.
The study was approved by the University of North Carolina Biomedical Institutional 
Review Board as well as the Wake County Human Services Board and conducted in 
accordance with The Code of Ethics of the World Medical Association.
Measures
The Edinburgh Postnatal Depression Scale (EPDS) (Cox et al. 1987) was used to assess 
PPD; it is a widely used measure and has been validated on Spanish-speaking populations 
(Garcia-Esteve et al. 2003). Compared to other depression measures, the EPDS relies less 
heavily on questions about somatic or physical symptoms of depression and includes several 
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items that specifically assess for symptoms of anxiety. A cut-off score of 12 or higher has 
consistently shown to correlate with a diagnosis of major depressive disorder (Cox et al. 
1987; Matthey et al. 2006; Murray and Carothers 1990). At 6- and 12-week follow-up visits, 
participants were asked how frequently they were: 1) bottle-feeding, 2) breastfeeding, or 3) 
breastfeeding and bottle-feeding.
Ghrelin Samples
sTwenty-four hour urinary samples were collected during pregnancy (baseline) and again at 
6-weeks postpartum. Only 24-hour urine collections ≥ 900 mL were considered valid. 
Samples were frozen at −80°C until assayed in batch. The 24-hour urine was carefully 
processed to maintain hormone integrity (i.e., prevent deactylation) by keeping it cold and 
acidic. Active ghrelin levels were measured using a commercially available competitive 
double antibody radioimmunoassay reagents and protocol (Millipore Corp, Billerica, MA). 
This assay has a standard curve ranging from 7.8 to 1000 pg/mL; the sensitivity of the assay 
is 7.8 pg/mL. The antibody cross-reacts 100% with the bioactive form of ghrelin with 
octanoyl group on serine 3, and with ghrelin 1–10; it reacts < 0.1% with des-octanoyl 
ghrelin, ghrelin 14–28, leptin, insulin, glucagon, and glucagon-like peptide 1 7–36. This 
assay has been shown to yield active ghrelin levels in urine comparable to those measured by 
high performance liquid chromatography (Aydin et al. 2008). However, because this assay 
was not designed for urine, we performed a dilution study and determined that a 1:1 to 1:3 
dilution in the assay buffer gave good reproducibility. Thus, a 1:1 dilution in assay buffer 
was used for this study. To examine the potential impact of fluid shifts during pregnancy, we 
examined both raw ghrelin levels and creatinine-adjusted levels as outcomes.
Statistical Analysis
We confirmed the normal distribution of our primary measures, EPDS and ghrelin, at 
pregnancy (i.e., skewness = 0.6 and −0.1, respectively) and, therefore, did not transform any 
variables prior to analysis. Because we consider our study exploratory, we chose a priori not 
to include any covariates in the models.
We created two dichotomous PPD variables. First, PPD status, based on the EPDS cut-off 
score such that those women scoring at or above the cut-off of 12 were coded as a positive 
screen for depression (‘1’) and those scoring below 12 were coded as a negative screen for 
depression (‘0’) during pregnancy and 6- and 12-weeks postpartum. Second, we created a 
variable, based on PPD status, to determine how many women reported change in depression 
status over the course of pregnancy and postpartum, “PPD-change:” 1) no depression at 
pregnancy or postpartum; 2) no depression at pregnancy, but PPD at 6- or 12-weeks 
postpartum; 3) depression at pregnancy and PPD at 6- or 12-weeks postpartum; 4) 
depression at pregnancy, but no PPD at 6- or 12-weeks postpartum. Because so few women 
reported breastfeeding only at 6- or 12-week follow-up (n=8 and 7, respectively), and 
because we found no differences in ghrelin as a function of the three feeding methods 
(1=bottle-feeding, 2=breastfeeding, 3=bottle- and breastfeeding), we collapsed groups 2 and 
3 to create two categories: bottle-feeding only and some combination of breastfeeding and 
bottle-feeding.
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We examined group differences, based on PPD status and PPD-change, in mean ghrelin 
concentrations using a mixed between-within subjects repeated measures analysis of 
variance and we examined the association between EPDS total score and ghrelin using linear 
regression. Next, we explored the change in ghrelin concentration from pregnancy to 6-
weeks postpartum using a paired samples t-test. Finally, an analysis of variance was used to 
examine mean differences in active ghrelin between women who strictly bottle-fed 
compared with women who breastfed or combined breastfeeding with bottle-feeding. All 
analyses were completed with both raw ghrelin levels and creatinine-adjusted ghrelin levels 
to understand our results within the context of the fluid shifts that occur in pregnancy and 
postpartum. Significance tests were two-tailed and significance was assessed at p < 0.05.
RESULTS
The mean EPDS score during pregnancy was 6.42 (SD=4.24) and at 6- and 12-weeks 
postpartum was 5.20 (SD=4.40) and 4.42 (SD=4.14), respectively. The percentage of women 
reporting an EPDS score at or greater than 12 (suggesting major depression) was 13.33% (n 
= 8) at baseline, 11.67% (n = 7) at 6-weeks postpartum, and 6.67% (n = 4) at 12-weeks 
postpartum. Three women reported pregnancy depression and remained depressed at 6- 
and/or 12-weeks postpartum, five reported pregnancy depression and no postpartum 
depression, and five reported no pregnancy depression but were depressed at 6- or 12-weeks 
postpartum.
Mean raw and creatinine-adjusted ghrelin concentrations based on PPD status and PPD-
change are shown in Tables 1 and 2, respectively. A significant mean difference in raw 
ghrelin concentration was observed at 12-weeks postpartum such that women screening 
positive for PPD at 12-weeks postpartum had higher mean active ghrelin concentration 
during pregnancy compared with women who did not screen positive for PPD at 12-weeks 
postpartum, F(1, 47)=5.12, p < .05. A trend (p = 0.05) was also observed for raw ghrelin 
levels at 6-weeks, with women screening positive for PPD having higher 6-week ghrelin 
concentrations than those not screening positive for PPD. Similarly, a significant interaction 
was observed between pregnancy PPD status and time, F(2, 47)=15.60, p < .01, suggesting 
that change in ghrelin levels from pregnancy to postpartum differ based on pregnancy 
depression status. Specifically, ghrelin concentrations decreased less in women who were 
depressed during pregnancy (M= −36.41; SD=21.40 pg/mL) compared with women who 
were not depressed during pregnancy (M= −47.30; SD=40 pg/mL). No significant 
associations emerged with raw ghrelin levels and PPD-change. When analyses were repeated 
with creatinine-adjusted ghrelin concentrations, no findings remained significant. Further, 
we observed no significant associations between pregnancy, 6-week postpartum, or 12-week 
postpartum EPDS total scores and raw or creatinine-adjusted ghrelin concentrations.
Finally, raw mean ghrelin concentrations significantly decreased from pregnancy 
(M=132.20, SD=28.37 pg/mL) to 6-weeks postpartum (M=88.47, SD=32.00 pg/mL), 
t(48)=8.83, p < .001. Results were similar for creatinine-adjusted ghrelin, which 
significantly decreased from pregnancy (M=128.00, SD=46.24 pg/mL) to 6-weeks 
postpartum (M=83.23, SD=29.00 pg/mL), t(49)=6.00, p < .0001. We also observed a 
significant mean difference in raw ghrelin levels at 6-weeks postpartum based on 
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breastfeeding status at 6-weeks postpartum, F(1, 47)=5.23, p < .05. Active ghrelin 
concentrations were lower in women who reported breastfeeding (M=84.40; SD=30.62 
pg/mL) compared with women who were bottle-feeding only (M=113.0; SD=31.00 pg/mL). 
However, no mean differences in creatinine-adjusted ghrelin concentrations based on breast-
feeding status were observed.
DISCUSSION
This study is the first, to our knowledge, to explore the relation between PPD and active 
ghrelin concentrations and adds to a small but growing literature describing longitudinal 
changes in active ghrelin from pregnancy to postpartum. We observed a higher pregnancy 
active ghrelin concentration among the subset of women who screened positive for PPD at 
12-weeks postpartum compared with those who screened negative for PPD. Thus, because 
raw ghrelin concentrations decrease from pregnancy to postpartum, women who have high 
active ghrelin levels during pregnancy and subsequently experience a decrease in ghrelin at 
postpartum may be especially vulnerable to depressive symptoms given the significant 
association between low ghrelin levels and depression in nonpregnant samples (Barim et al. 
2009).
It was also observed that raw ghrelin concentrations change from pregnancy to postpartum 
differently in women who were depressed during pregnancy compared with those women 
who were not depressed at pregnancy. Examining mean change scores in ghrelin levels from 
pregnancy to postpartum indicated that women who were depressed during pregnancy 
experienced less change in ghrelin levels between pregnancy to postpartum. Importantly 
however, when ghrelin levels were adjusted for creatinine our findings were no longer 
significant. Given that creatinine can be considered a marker of renal function and fluid 
retention, this suggests that the fluid shifts that occur during pregnancy and postpartum are 
an important factor in ghrelin levels and may entirely account for the association between 
ghrelin and depression during the pregnancy and postpartum period.
Our findings suggest that active ghrelin (both raw and creatinine-adjusted levels) decreases 
from pregnancy to 6-weeks postpartum; as such, they are contrary to previous observations 
suggesting an increase in active ghrelin from pregnancy to 24 hours postpartum (Baykus et 
al. 2012), but consistent with those indicating decreased active ghrelin at 30 to 180 days 
postpartum (Ilcol and Hizli 2007). This time course (i.e., an initial spike in active ghrelin 
levels postpartum followed by a continual decrease over time) makes physiological sense 
from the perspective of ghrelin facilitating adequate food intake to meet the energy demands 
of mother and infant and to support milk production during a critical window for 
establishing breastfeeding and later returning food intake and weight to homeostasis over 
time.
Consistent with previous research we observed that women who were breastfeeding at 6-
weeks postpartum had lower raw active ghrelin concentrations than women who were bottle-
feeding only. This finding does corroborate a previous report showing that active ghrelin 
concentrations steadily decreased in breastfeeding women over a period of 180 days (Ilcol 
and Hizli 2007). Similarly, lactating women (Aydin et al. 2006; Ilcol and Hizli 2007; Larson-
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Meyer et al. 2010) and animals (Shibata et al. 2004) have decreased ghrelin concentrations. 
Active ghrelin concentrations may decrease in breastfeeding women secondary to 
diminished estradiol concentrations in women (McNeilly et al. 1994), as estradiol may play 
a role in ghrelin production (Kellokoski et al. 2005; Sakata et al. 2006). In turn, diminished 
circulating active ghrelin may play a role in postpartum weight loss in breastfeeding women, 
who tend to retain less pregnancy weight compared to non-breastfeeding women (Baker et 
al. 2008; Olson et al. 2003). However, we did not observe significant differences in ghrelin 
concentrations based on breastfeeding status in creatinine-adjusted ghrelin levels again 
suggesting the potential importance of pregnancy and postpartum renal function on ghrelin 
levels.
Several limitations of this study should be noted. First, and foremost is our sample size. 
Because of our small sample size of women with PPD, results should be interpreted with 
caution. Second, it is also possible that our preliminary study was underpowered to detect 
significant effects. Third, the larger parent study was an enriched sample of women with 
depression during pregnancy. Thus, findings may not generalize to epidemiological samples. 
Fourth, not assessing active ghrelin beyond postpartum week six prevented us from 
exploring potentially interesting questions about associations between ghrelin and 
depression further into the postpartum period. Fifth, we only assayed active ghrelin 
concentrations and did not have information on total ghrelin (sum levels of both the active 
and inactive forms) concentrations. Since active and total ghrelin are differentially regulated 
in breastfeeding women and are differentially associated with ghrelin levels in breast milk 
(Ilcol and Hizli 2007), future studies examining both active and total ghrelin in women with 
PPD who do and do not breastfeed would be worthwhile. Further, due to the limited number 
of women reporting breastfeeding only, we had to combine those women who were 
breastfeeding only and those who were engaging in a combination of breastfeeding and 
bottle-feeding. We may have found results in line with previous studies if our sample size of 
breastfeeding only women was larger. Finally, although the cut-off used for the EPDS score 
in this report is a well-established cut-off suggestive of PPD, the use of cut-offs could have 
impacted findings such that we may have observed differing findings with a different cut-off 
(e.g., score of 11 or 13 versus 12).
Taken together, our results, in general, suggest that once renal function is accounted for, 
there is no significant association between ghrelin concentration and PPD. It will be 
important for future research to consider renal function and creatinine levels when assessing 
the association between ghrelin and depression. Because PPD can have serious 
consequences for mother and infant, it is imperative that we improve our knowledge of the 
biological factors associated with PPD. Future studies that extend further across the 
postpartum period, assess total and active ghrelin concentrations, evaluate depression by 
diagnostic interview rather than self-report, and include larger cohorts of breastfeeding and 
bottle-feeding mothers in epidemiological samples are needed before we will be able to 
draw definitive conclusions about the association between PPD and ghrelin.
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